Cardioprotective effects of inhaled corticosteroid-containing combination therapy in COPD

Brian J. Lipworth (Lead / Corresponding author), Chris R. W. Kuo

Research output: Contribution to journalLetterpeer-review

1 Citation (Scopus)
44 Downloads (Pure)


The pooled post hoc analysis of three randomised controlled trials by Vestbo et al. [1] found that combinations containing inhaled corticosteroid (ICS) significantly reduced non-respiratory-related mortality in chronic obstructive pulmonary disease (COPD) compared to long-acting bronchodilator therapies alone, the difference amounting to −35% (95% CI −57% to −3%). These studies did not adjudicate on cause of death and only followed patients for up to 1 year. In the IMPACT trial, all-cause mortality was 42% lower and cardiovascular attributed deaths were 52% lower when comparing triple therapy to combined long-acting bronchodilators over 1 year [2].
Original languageEnglish
Article number1802420
JournalEuropean Respiratory Journal
Issue number2
Publication statusPublished - 1 Feb 2019

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Cardioprotective effects of inhaled corticosteroid-containing combination therapy in COPD'. Together they form a unique fingerprint.

Cite this